Evaluation of ARI-3037MO, to Suppress LDL Cholesterol in Patients With Dyslipidemia
A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 176 participants.
Also called NCT02532218
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 176 participants
- Sponsor
- Arisaph Pharmaceuticals Inc
- Registry
-
NCT02532218
-
- Start date
- (registry gives no type)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Unknown status
Technical summary
Registry record NCT02532218. Randomized; quadruple masking; primary purpose treatment. Start 2015-08 (registry gives no type); primary completion 2016-09 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Evaluation of ARI-3037MO, to Suppress LDL Cholesterol in Patients With Dyslipidemia
- Acronym
- REASCEND
- Condition
- Hyperlipidemia
- Intervention (Drug)
- ARI-3037MO
- Lead sponsor
- Arisaph Pharmaceuticals Inc
Record details
- Record id
cardio:ct-nct02532218- Content hash
0f58cd444749accbc8c80665ee5bc14ced2f09459aa569ac37980f6b382871c8